A
Atanas Kamburov
Researcher at Bayer
Publications - 5
Citations - 176
Atanas Kamburov is an academic researcher from Bayer. The author has contributed to research in topics: Cancer & Downregulation and upregulation. The author has an hindex of 3, co-authored 5 publications receiving 88 citations. Previous affiliations of Atanas Kamburov include Broad Institute.
Papers
More filters
Journal ArticleDOI
ERCC2 Helicase Domain Mutations Confer Nucleotide Excision Repair Deficiency and Drive Cisplatin Sensitivity in Muscle-Invasive Bladder Cancer
Qiang Li,Qiang Li,Alexis W. Damish,Zoë Frazier,David Liu,David Liu,Elizaveta Reznichenko,Elizaveta Reznichenko,Atanas Kamburov,Atanas Kamburov,Andrew C. Bell,Huiyong Zhao,Emmet Jordan,S. Paul Gao,Jennifer Ma,Philip Abbosh,Philip Abbosh,Joaquim Bellmunt,Elizabeth R. Plimack,Jean-Bernard Lazaro,Jean-Bernard Lazaro,David B. Solit,David B. Solit,Dean F. Bajorin,Jonathan E. Rosenberg,Alan D. D'Andrea,Alan D. D'Andrea,Nadeem Riaz,Eliezer M. Van Allen,Eliezer M. Van Allen,Gopa Iyer,Kent W. Mouw,Kent W. Mouw +32 more
TL;DR: The data support a direct role for ERCC2 mutations in driving cisplatin response, define the functional landscape of ERCC1 mutations in bladder cancer, and provide an opportunity to apply combined genomic and functional approaches to prospectively guide therapy decisions in bladder cancers.
Journal ArticleDOI
Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Maria Quanz,Eckhard Bender,Charlotte Kopitz,Sylvia Grünewald,Andreas Schlicker,Wolfgang Schwede,Ashley Eheim,Luisella Toschi,Roland Neuhaus,Carmen Richter,Joern Toedling,Claudia Merz,Ralf Lesche,Atanas Kamburov,Holger Siebeneicher,Marcus Bauser,Andrea Hägebarth +16 more
TL;DR: In order to address potential acquired resistance mechanisms to MCT1 inhibition, it is shown that resistance can occur by upregulation of MCT4 even in the presence of sufficient oxygen, as well as by shifting energy generation toward oxidative phosphorylation.
Journal ArticleDOI
Identification of Small Molecules that Modulate Mutant p53 Condensation.
Clara Lemos,Luise Schulze,Joerg Weiske,Hanna Meyer,Nico Braeuer,Naomi Barak,Uwe Eberspächer,Nicolas Werbeck,Carlo Stresemann,Martin Lange,Ralf Lesche,Nina Zablowsky,Katrin Juenemann,Atanas Kamburov,Laura M. Luh,Thomas Markus Leissing,Jérémie Mortier,Michael Steckel,Holger Steuber,Knut Eis,Ashley Eheim,Patrick Steigemann +21 more
TL;DR: This study shows condensate-like states of fluorescently labeled structural mutant p53 in the nucleus of living cancer cells and identified small molecule compounds that interact with the p53 protein and lead to dissolution of p53 structural mutant condensates.
Journal ArticleDOI
ConsensusPathDB 2022: molecular interactions update as a resource for network biology.
Atanas Kamburov,Ralf Herwig +1 more
TL;DR: ConsensusPathDB (http://consensuspathdb.org) is a meta-database combining interactions of diverse types from 31 public resources for humans, 16 for mice and 14 for yeasts as discussed by the authors.
Proceedings ArticleDOI
Abstract 3080: Activity of pan-FGFR inhibitor rogaratinib and PI3K inhibitor copanlisib in preclinical urothelial bladder cancer models
Isabel S. Jerchel,Pascale Lejeune,Rita Lampignano,Alexander Walter,Ralf Lesche,Atanas Kamburov,Dominik Mumberg,Peter Ellinghaus,Oliver Politz,Sylvia Gruenewald +9 more
TL;DR: In UBC tumor models overexpressing FGFR with differing sensitivities to rogaratinib, its anti-tumor activity could be further enhanced when combined with copanlisib and suggests that PIK3CA mutations may play a role in reduced sensitivity of UBC to FGFR inhibition.